Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.humpath.2024.105712 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive genomic profiling and clinico-pathologic characterization of primary ovarian leiomyosarcoma.
Int J Gynecol Cancer
September 2025
Fondazione Policlinico Universitario A. Gemelli, IRCCS, Department of Woman and Child, and Public Health, Division of Gynecologic Oncology, Rome, Italy.
Objective: Primary ovarian leiomyosarcomas are exceptionally rare, accounting for less than 0.1% of ovarian malignancies. Their treatment strategies remain poorly defined, and data on comprehensive genomic profiling are lacking.
View Article and Find Full Text PDFMucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.
JCO Precis Oncol
August 2025
Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada.
Purpose: Epithelioid sarcoma (ES) and malignant rhabdoid tumor (MRT) are rare soft tissue sarcomas with poor prognoses. Although mucin 16 (MUC16) and its soluble form, cancer antigen 125 (CA125), are established as biomarkers and therapeutic targets in ovarian cancer, emerging data suggest MUC16 may also be expressed in ES and MRT. In this study, we present a patient with ES, who demonstrated a response to ubamatamab, a novel bispecific T-cell engager (MUC16xCD3), and analyze treatment resistance after disease progression.
View Article and Find Full Text PDFTrivalent bispecific anti-MSLN/CD3 antibody for cancer treatment.
Pharm Pat Anal
August 2025
Innovation and Knowledge Transfer Department, Benemerita Autonomous University of Puebla, Puebla, México.
Introduction: Mesothelin protein is an overexpressed molecule in epithelioid mesothelioma, epithelial ovarian cancer, and pancreatic adenocarcinoma, which is why it is considered a potential therapeutic target.
Areas Covered: WO2024082060 patent describes a trivalent bispecific antibody directed against MSLN/CD3/MSLN, and lung cancer treatment method. This antibody exhibits binding activity to MSLN-containing tumor cells, as well as inhibition of tumor growth rate in murine models of lung and ovarian cancer.
PTCH1::GLI1 Fusion Tumors of the Ovary: A Clinicopathologic Study of 3 Cases.
Int J Gynecol Pathol
July 2025
The Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
GLI1-altered tumors of the gynecologic tract are extremely rare. We report 3 cases of ovarian PTCH1::GLI1 fusion tumor in patients ranging from 54 to 58 yrs of age, who presented with unilateral FIGO stage I tumors. The tumors ranged from 12 to 20 cm and consisted of uniform epithelioid cells with eosinophilic/clear cytoplasm, arranged in nests and trabeculae surrounded by delicate vessels.
View Article and Find Full Text PDFDiagnostic Challenges in Lymphangioleiomyomatosis: From Ovarian Mass to Systemic Diagnosis.
Acta Med Litu
February 2025
Clinic of Obstetrics and Gynaecology, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.
Background: (LAM) is a rare neoplastic disorder characterized by the proliferation of atypical smooth muscle-like or epithelioid cells within the lungs and axial lymphatic system. This pathological process leads to the formation of pulmonary cysts and impaired respiratory function. Although the disease primarily involves the lungs, extrapulmonary manifestations can occur in the abdominal cavity, lymphatic system, and retroperitoneum.
View Article and Find Full Text PDF